For more information please call us at +44(0) 800-130-0857
or for the US dial
+44 800-130-0857
*This number is not toll free if dialed from the US. Regular charges will apply.
InnoSpire Go portable mesh nebulizer provides an easy therapy experience, which helps your patients administer therapy correctly. Utilizing established, clinically proven Aerogen Vibronic® vibrating mesh technology adopted by hospitals worldwide, InnoSpire Go delivers all commonly prescribed respiratory medications. The easy-to-use and virtually silent InnoSpire Go has been specifically designed to shorten nebulizer treatment times, giving your patients more time for life.
*versus predecessor Aeroneb Go
State-of-the-art, regulatory compliant laboratory testing facilities offering feasibility, development and submission studies by aerosol specialists.
Download our device decision tree to help determine which product may be best suited to meet your drug delivery needs.
Mesh devices should be considered as a first choice when looking at inhaled drug delivery. Devices with different modes of operation (active and passive vibrating mesh) are capable of delivering a variety of pharmaceutical formulations with a wide range of physichemical characteristics.
I-neb AAD System
Domiciliary Experience of the Target Inhalation Mode (TIM) Breathing Maneuver in Patients with Cystic Fibrosis Denyer J, Black A, Nikander K, Dyche T, Prince I. J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S45-S54 | Mode of Breathing—Tidal or Slow and Deep—through the I-neb Adaptive Aerosol Delivery (AAD) System Affects Lung Deposition of 99mTc-DTPA Nikander K, Prince I, Coughlin S, Warren S, Taylor G. J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S37-S43 |
Evaluation of Patient-Reported Outcomes and Quality of Life with the I-neb AAD System in Patients with Chronic Obstructive Pulmonary Disease Goodman N, Morgan M, Nikander K, Hinch S, Coughlin S. J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S61-S70 | The Adaptive Aerosol Delivery System in a Telehealth Setting: Patient Acceptance, Performance and Feasibility Nikander K, Denyer J, Dodd M, Dyche T, Webb K, Weller P, Stableforth D. J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S21-S27 |
Evaluation of the Target Inhalation Mode (TIM) Breathing Maneuver in Simulated Nebulizer Therapy in Patients with Cystic Fibrosis Denyer J, Prince I, Dixon E, Agent P, Pryor J, Hodson M. J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S29-S36 | The Adaptive Aerosol Delivery (AAD) Technology: Past, Present, and Future. Denyer J, Dyche T. J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S1-S10 |
In Vitro Characterization of the I-neb Adaptive Aerosol Delivery (AAD) System Hardaker LEA, Hatley RHM. J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S11-S20 | The I-neb Adaptive Aerosol Delivery System Enhances Delivery of α1-Antitrypsin with Controlled Inhalation Geller DE, Kesser KC. J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S55-S59 |
OptiChamber Diamond Valved Holding Chamber
In Vitro Characterization of the OptiChamber Diamond Valved Holding Chamber Hatley RHM, von Hollen D, Sandell D, Slator L. J Aerosol Med Pulm Drug Deliv. 2014; 27(Suppl 1):S24-S36 | Development of Inhaled Pharmaceuticals
Rethinking the Paradigm for the Development of Inhaled Drugs Pritchard J. International Journal of Pharmaceuticals. 2015; 496:1069-1072 |
Domiciliary Experience of the Target Inhalation Mode (TIM) Breathing Maneuver in Patients with Cystic Fibrosis
Denyer J, Black A, Nikander K, Dyche T, Prince I.
J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S45-S54
Evaluation of Patient-Reported Outcomes and Quality of Life with the I-neb AAD System in Patients with Chronic Obstructive Pulmonary Disease
Goodman N, Morgan M, Nikander K, Hinch S, Coughlin S.
J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S61-S70
Evaluation of the Target Inhalation Mode (TIM) Breathing Maneuver in Simulated Nebulizer Therapy in Patients with Cystic Fibrosis
Denyer J, Prince I, Dixon E, Agent P, Pryor J, Hodson M.
J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S29-S36
In Vitro Characterization of the I-neb Adaptive Aerosol Delivery (AAD) System
Hardaker LEA, Hatley RHM.
J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S11-S20
Mode of Breathing—Tidal or Slow and Deep—through the I-neb Adaptive Aerosol Delivery (AAD) System Affects Lung Deposition of 99mTc-DTPA
Nikander K, Prince I, Coughlin S, Warren S, Taylor G.
J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S37-S43
The Adaptive Aerosol Delivery System in a Telehealth Setting: Patient Acceptance, Performance and Feasibility
Nikander K, Denyer J, Dodd M, Dyche T, Webb K, Weller P, Stableforth D.
J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S21-S27
The Adaptive Aerosol Delivery (AAD) Technology: Past, Present, and Future.
Denyer J, Dyche T.
J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S1-S10
The I-neb Adaptive Aerosol Delivery System Enhances Delivery of α1-Antitrypsin with Controlled Inhalation
Geller DE, Kesser KC.
J Aerosol Med Pulm Drug Del. 2010;23(Suppl 1):S55-S59
OptiChamber Diamond Valved Holding Chamber
In Vitro Characterization of the OptiChamber Diamond Valved Holding Chamber
Hatley RHM, von Hollen D, Sandell D, Slator L.
J Aerosol Med Pulm Drug Deliv. 2014; 27(Suppl 1):S24-S36
Development of Inhaled Pharmaceuticals
Rethinking the Paradigm for the Development of Inhaled Drugs
Pritchard J.
International Journal of Pharmaceuticals. 2015; 496:1069-1072
With a line of sturdy and easy to use products, our respiratory drug delivery products help empower patients to monitor their condition and to take their medication.
Lightweight, versatile, and easy to use, our ventilators provide invasive and noninvasive ventilator support for a wide range of adult and pediatric patients.
With stationary and portable oxygen therapy options, our products are intended to give users the flexibility they want, while helping reduce expenses for providers.